ARC Linkage - $290,000

Many macroscopic aspects of pMDI for respiratory diseases are recognised, but are yet to be understood at the basic level and accordingly exploited. In particular, the droplet charge mechanism in non-aqueous pMDIs remains elusive. Currently, although a wide range of drugs are commercially available as pMDIs, the efficiency of these systems is poor, with most devices delivering less than 20% to the lung. An insight into these systems is crucial to successfully enhance the performance of aerosol formulations in industry, ultimately translating in superior patient therapy. This project will create a theoretical model for pMDI formulation that can be applied to the development of a new generation of inhalation medicines.